Activation of systemic antitumor immunity via TRAIL-induced apoptosis

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1178-1180

  James, Britnie R ^a   Griffith, Thomas S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adenovirus; Apoptosis; Immunotherapy; RCC; TRAIL

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC AGENT; HISTONE DEACETYLASE INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ADENOVIRUS INFECTION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INFILTRATION; CANCER RESISTANCE; CANCER SURVIVAL; DISTANT METASTASIS; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VIRUS INFECTIVITY;

EID: 84880154163     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20638     Document Type: Article

References (10)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C P, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apop-tosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10.1016/1074-7613(95)90057-8.
2. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165:2886-94; PMID:10946322.
3. Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001; 4:257-66; PMID:11545617; http://dx.doi.org/10.1006/mthe.2001.0439.
4. Shirota H, Klinman DM. CpG-conjugated apop-totic tumor cells elicit potent tumor-specific immunity. Cancer Immunol Immunother 2011; 60:659-69; PMID:21318638; http://dx.doi.org/10.1007/s00262-011-0973-y.
5. VanOosten RL, Griffith TS. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/ CpGoligodeoxynucleotide combination therapy. Cancer Res 2007; 67:11980-90; PMID:18089829; http://dx.doi.org/10.1158/0008-5472.CAN-07-1526.
6. Norian LA, Kresowik T P, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, et al. Eradication of meta-static renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/ CpG immunotherapy. PLoS One 2012; 7:31085; PMID:22312440; http://dx.doi.org/10.1371/journal.pone.0031085.
7. Holoch PA, Griffith TS. TNF-related apoptosis-induc-ing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol 2009; 625:63-72; PMID:19836385; http://dx.doi.org/10.1016/j.ejphar.2009.06.066.
8. Yamano T, Ura K, Morishita R, Nakajima H, Monden M, Kaneda Y. Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 2000; 1:574-80; PMID:10933982; http://dx.doi.org/10.1006/mthe.2000.0074.
9. VanOosten RL, Moore JM, Karacay B, Griffith TS. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer BiolTher 2005; 4:1104-12; PMID:16096370; http://dx.doi.org/10.4161/cbt.4.10.2022.
10. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1:287-99; PMID:12120280; http://dx.doi.org/10.1038/nrd772.